Calidi Biotherapeutics Secures $2 Million Through Share Offering
Calidi Biotherapeutics, Inc. (NYSE: CLDI), a pioneering clinical-stage biotechnology company focused on targeted immunotherapies, has recently made headlines with its announcement regarding a significant share sale. In a calculated move for growth, Calidi has entered into a definitive securities purchase agreement with various institutional investors to sell 2,050,000 shares of its common stock. Each share will be priced at $1.00, all part of a registered direct offering.
Concurrently Planned Private Placement
In addition to the registered direct offering, the company is also conducting a concurrent private placement. Through this arrangement, Calidi plans to issue series E and series F warrants to these investors, allowing them to purchase up to 2,050,000 shares of common stock. Notably, both series E and series F warrants will have an exercise price of $1.13 per share. These warrants are set to be exercisable six months after issuance and come with varying terms to suit investor needs.
Proceeds for Growth and Development
The financial implications of this offering are promising for Calidi. Anticipated gross proceeds of roughly $2 million from both the registered direct offering and the private placement will empower the company to enhance its working capital. In addition, these funds are earmarked to support essential corporate purposes and also aid in ongoing pre-clinical and clinical trials.
Regulatory Compliance and Upcoming Milestones
These securities offerings are being conducted in alignment with a shelf registration statement that was declared effective by the United States Securities and Exchange Commission (SEC). This ensures compliance and gives potential investors confidence in the company’s efforts to maintain transparency and accountability in its financial operations. The anticipated closing of these offerings should occur shortly, pending the usual closing conditions.
About Calidi Biotherapeutics
Founded with an innovative vision, Calidi Biotherapeutics is at the forefront of immuno-oncology, leveraging its proprietary technology to enhance the immune system’s ability to combat cancer. Their advanced stem cell-based platform is capable of delivering potent oncolytic viruses to target various cancer types, including serious conditions like high-grade gliomas and solid tumors. With their focus on developing off-the-shelf virotherapies, the objective is to not only treat existing conditions but also aim for preventive measures against metastatic diseases.
Innovative Therapeutic Strategies
Calidi’s unique platform strives to protect, magnify, and enhance the efficacy of oncolytic viruses, promoting safer and more effective treatments for patients. The company’s approach distinguishes itself through its dual-targeting method, potentially leading to groundbreaking alternatives in cancer therapy.
Company Outlook
As Calidi Biotherapeutics continues to navigate through its clinical trials and advancements in treatment methodologies, the recent funding serves as a pivotal moment for growth and innovation. Stakeholders and investors are eagerly watching the company's trajectory as it seeks to make significant contributions to oncology and beyond.
Frequently Asked Questions
What is the purpose of Calidi's recent $2 million offering?
The funds will finance working capital, corporate purposes, and clinical trials, enhancing the company's research efforts.
What kind of securities are being offered?
Calidi is offering shares of common stock and warrants as part of a registered direct offering and private placement.
When is the expected closing for these offerings?
The closing is expected to take place around the end of October, based on the satisfaction of customary conditions.
What technology does Calidi Biotherapeutics specialize in?
Calidi focuses on immunotherapies utilizing stem cell-based platforms to fight various cancers.
Where is Calidi Biotherapeutics headquartered?
The company is headquartered in San Diego, California, driving innovation in cancer treatment.
